What is the difference between ACE-031 and Follistatin 344?

ACE-031: Soluble decoy receptor for ActRIIB; sequesters myostatin, activin, and GDF-11 to remove multiple brakes on muscle and bone growth simultaneously Follistatin 344: Binds and neutralizes myostatin (GDF-8) and activin; removes the natural brake on muscle growth allowing supraphysiological hypertrophy

Is ACE-031 FDA approved?

ACE-031 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is Follistatin 344 FDA approved?

Follistatin 344 is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is ACE-031 administered in research settings?

In research settings, ACE-031 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Follistatin 344 administered in research settings?

In research settings, Follistatin 344 is typically administered via the intramuscular route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›ACE-031 vs Follistatin 344

Peptide Comparison

ACE-031 vs Follistatin 344

Name: ACE-031 vs Follistatin 344 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Muscle & Myostatin peptides.

ACE-031

ACVR2B-Fc

PerformanceInvestigationalResearch Only

Half-life: ~14 days

4 providers listed

Full ACE-031 profile →

Follistatin 344

FST-344

PerformanceNot EvaluatedResearch Only

Half-life: ~24-36 hours

15 providers listed

Full Follistatin 344 profile →

Bottom line

ACE-031 has published research citations on file; Follistatin 344 does not yet — the main evidence gap between them.

Quick Verdict

ACE-031

Half-life

~14 days

Follistatin 344

Half-life

~24-36 hours

Which One Should You Choose?

Your goal	Better option
Has published research citations	ACE-031
Further along in FDA review	ACE-031
Less frequent dosing (longer half-life)	ACE-031
More provider options (4 vs 15)	Follistatin 344

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

ACE-031

Follistatin 344

Mechanism Family

Muscle & Myostatin

Half-life

~14 days

~24-36 hours

FDA Status

investigational

not evaluated

Admin Routes

subcutaneous, intravenous

intramuscular

Availability

Research Only

Providers

4 listed

15 listed

Avail. Notes

Activin receptor IIB-Fc fusion (ACVR2B decoy) by Acceleron Pharma. Phase 2 for Duchenne MD halted 2013 due to AEs (epistaxis, telangiectasia). Development discontinued. Previously held IND.

Myostatin inhibitor. No FDA approval. Gene therapy forms in early trials but recombinant protein is a research chemical. WADA prohibited. No NDA or IND for peptide form.

Research Evidence

ACE-031

RCT · 1 key study · most recent 2017

Follistatin 344

No citations on file

Research Citations

ACE-031

RCT2017 · Muscle & Nerve

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a rando…

Follistatin 344

No citations on file.

About ACE-031

Soluble decoy receptor for ActRIIB; sequesters myostatin, activin, and GDF-11 to remove multiple brakes on muscle and bone growth simultaneously

Research Areas

myostatin/activin inhibitionmuscle mass increasebone density improvement

About Follistatin 344

Binds and neutralizes myostatin (GDF-8) and activin; removes the natural brake on muscle growth allowing supraphysiological hypertrophy

Research Areas

myostatin and activin A neutralization — dual TGF-β inhibitionskeletal muscle hypertrophy in transgenic animal modelssatellite cell activation and muscle protein synthesis reliefgene therapy context: Becker MD phase 1/2a trial safety established

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

ACE-031

Reported (Unverified — Pending Clinical Review)

cardiovascular diseasetelangiectasia riskbleeding disorderspregnancy

No established clinical contraindications

Follistatin 344

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Price (per mg)

ACE-031

$119.00/mg

$78.70 – $161.50 range

8 vendors

View price index →Find providers →

Follistatin 344

$102.67/mg

$90.00 – $139.00 range

12 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

ACE-031

4 listed

Browse directory →

Providers offering

Follistatin 344

15 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Muscle & Myostatin Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). ACE-031 vs Follistatin 344 — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/ace-031/follistatin-344

https://peptidebase.io/peptides/compare/ace-031/follistatin-344 Methodology License Download JSON Download CSV